Literature DB >> 7038041

Antibody and cytotoxic T lymphocyte responses of humans to live and inactivated influenza vaccines.

F A Ennis, Q Yi-Hua, G C Schild.   

Abstract

The antibody and HLA-restricted virus-specific cytotoxic T lymphocyte (CTL) responses to influenza vaccine of 36 volunteers were analysed. Three vaccines were used: a live attenuated, and two types of inactivated, a whole virus and a purified surface antigen vaccine. Antibody to haemagglutinin (HA) was assayed using plaque neutralization, single-radial-haemolysis and haemagglutination-inhibition (HI) techniques. Antibodies to nucleoprotein and matrix antigens were also measured. Most of the volunteers had antibody responses to the HA in the inactivated vaccines which were detected by all three techniques. Nine of the twelve recipients of the live virus vaccine did not have an antibody response detected by the HI test, but four of these did have antibody responses when the plaque neutralization test was used. Single-radial-haemolysis was more sensitive than the HI test for detecting low levels of antibody, but the plaque neutralization test was the most sensitive for detecting low levels of antibody. Most volunteers had a rise in their HLA-restricted influenza-specific memory CTL response, but three recipients of live vaccine who did not have an antibody response by any technique also did not have an increase in their cytotoxic T cell activity. Three volunteers, two of whom had received live vaccine, had a positive CTL response without antibody response.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7038041     DOI: 10.1099/0022-1317-58-2-273

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  13 in total

1.  Immunization of elderly volunteers with the 1988-89 inactivated whole influenza vaccine: assessment of antibody responses by haemagglutination inhibition and single radial haemolysis tests.

Authors:  A M Iorio; T Zei; M Neri; L Campitelli; M R Castrucci; I Donatelli
Journal:  Eur J Epidemiol       Date:  1992-07       Impact factor: 8.082

Review 2.  Some newly recognized aspects of resistance against and recovery from influenza.

Authors:  A Ennis
Journal:  Arch Virol       Date:  1982       Impact factor: 2.574

3.  Regulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance.

Authors:  Mark W Lamere; Amy Moquin; F Eun-Hyung Lee; Ravi S Misra; Patrick J Blair; Laura Haynes; Troy D Randall; Frances E Lund; Denise A Kaminski
Journal:  J Virol       Date:  2011-03-02       Impact factor: 5.103

4.  Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus.

Authors:  Mark W LaMere; Ho-Tak Lam; Amy Moquin; Laura Haynes; Frances E Lund; Troy D Randall; Denise A Kaminski
Journal:  J Immunol       Date:  2011-02-25       Impact factor: 5.422

5.  Enhancement of anti-influenza A virus cytotoxicity following influenza A virus vaccination in older, chronically ill adults.

Authors:  G J Gorse; R B Belshe
Journal:  J Clin Microbiol       Date:  1990-11       Impact factor: 5.948

6.  Influenza vaccination in older patients. Immunogenicity, epidemiology and available agents.

Authors:  H Glathe; W Lange
Journal:  Drugs Aging       Date:  1995-05       Impact factor: 3.923

7.  Influenza vaccination in the elderly: seeking new correlates of protection and improved vaccines.

Authors:  Janet E McElhaney
Journal:  Aging health       Date:  2008-12-01

8.  Evaluating a surrogate endpoint at three levels, with application to vaccine development.

Authors:  Peter B Gilbert; Li Qin; Steven G Self
Journal:  Stat Med       Date:  2008-10-15       Impact factor: 2.373

9.  The sensitization of mice with a wild-type and cold-adapted variant of influenza A virus. II. Secondary cytotoxic T cell responses.

Authors:  N K Mak; C Sweet; G L Ada; G A Tannock
Journal:  Immunology       Date:  1984-02       Impact factor: 7.397

10.  Antibodies against conserved antigens provide opportunities for reform in influenza vaccine design.

Authors:  Denise A Kaminski; F Eun-Hyung Lee
Journal:  Front Immunol       Date:  2011-12-16       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.